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the past 2 years. Seven patients were excluded due to non-engraft- 
ment (3), progressive disease necessitating regimen change (2), or 
early death (2). Of  the 12 children included in the study, ages 
ranged from 2 to 22 years (median=I0).  The  male:female 
ratio=7:5. Stenr cell source was PBSC in all cases. Donor type was 
unrelated in 5 cases and related in 7. Reasons for R I -HSCT were: 
ALL(3), NHL(1), ANLL(I),  neuroblastoma (2), SCA(1), 1[3-tha- 
lassemia (1), Sandhoff syndrome(l) and Hyper IgM syndrome (2). 
All patients received conditioning regimens consisting of fludarib- 
ine (30 mg/m2/d X 6), busulfan (1 mg/kg q6 hr IV x 8), and ATG 
(40 mg/kg/d x 4). Cyclosporin (3mg/kg/dose BID)was used as 
GVI tD prophylaxis. Acute GVHD (aGVHD) occurred among 7 
of the 12 patients (incidence=58%); 3 grade Ii, 3 grade IlI, and 1 
grade IV. As expected, aGVHD was more frequent among recipi- 
ents of unrelated transplants; all 5 unrelated RI -HSCT recipients 
developed aGVHD vs. only 2 out of 7 related transplants (p=0.05). 
Complete engraftment was defined as an ANC greater than 500 
and more tllan 75% donor T lymphocytes based on VNTR.  Eight 
patients attained complete ngraftment by 40 days post-transplant 
and 4 patients were much later than 40 days (+108, 127, and 203) 
or not at all (1 long-term stable chimera). Six of the 8 patients 
who engrafted before day 40 developed aGVHD compared to 
only 1 case of aGVHD among the late engrafters (p=0.3). Chronic 
GVHD (cGVHD) occurred among 6 of the 10 evaluable patients 
(incidence=60%); 5 of these occurred among the 6 early engrafters 
vs only 1 cGVHD case among the 3 late engrafters (p=0.24). Of 
the 8 early engrafters, 4 are deceased and 4 are alive with cGVH. 
Among the 4 late engrafters, all are alive; 1 has cGVHD and 1 has 
had progression of Sandhoff syndrome. Although the data did not 
reach statistical significance within this small sample size, the 
results do support an association between the rapidity of engraft- 
ment and the development of acute and chronic GVHD among 
recipients of RI-HSCT. Further studies are warranted to more 
fillly address this issue. 
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ANTI-THYMOCYTE GLOBULIN (ATG), LOW DOSE TBI AND FLUDARA- 
BINE (FLU) CONDITIONING FOR ALLOGENEIC TRANSPLANTATION 
Lrola, L.; Scigliallo, E.; Fl"uchtlmlJz, S.; GJ'ossk~'eutz, C. . 
Non-myeloablative allogeneic PBPC transplant using low dose 
TBI (200 cGy) plus FLU results in lnodest rejection rates. Acute 
and chronic GvHD do not differ substantially from fully ablative 
transplantation. Adding ATG to conditioning produces substan- 
tial host immunosuppression a d in-vivo graft T ceil depletion. 
Twenty-five pts, not eligible for conventional allogeneic SCT by 
virtue of age or co-morbidities, underwent non-myeloablative 
transplantation using ATG 15 mg/kg/day days-4 to- l ,  TBI 200 
cGy on a single fi'action on day -5, fludarabine 301ng/kg/day on 
days-4 to-2. Oral MMF 15 mg/kg/dose Q 12 hrs and CSA 6 
mg/kg/dose Q 12 hrs were started on day-5. Grafts were PBPC 
nmbilized with filgrastim 10 mcg/kg/day. Median age was 53 (30- 
66), diagnoses were 11-NHI,, 6-AML, 3-MM, 1-SAA, 1-PNH 
and 1-MDS. Median CD34+ and CD3+ contents were 
9.05x106/kg and 1.64x108/kg respectively. Three pts (2 with 
VUDs and 1 with a sib donor) received 1 Ag misuratched graft. 
The rest were fully matched. Five pts received VUD grafts. 
Twenty-two pts were evaluable for chimerism: 20 had >98% 
donor chimerism, one 85% and one 23%. Nine pts. relapsed. One 
pt rejected the graft at 180 days. Median hospital stay was 27 days. 
Complications were: GvHD in 6 pts (3 pts had GI-II GvHD of 
skin and liver and 3 pts had GI I I - IV GvHD of liver and gut). 
Three of the pts with GvHD had mismatched grafts. Transplant 
related toxicity was seen in 4 pts and infection in 5 pts. Median 
follow up was 153 days (17-774). CR was seen in 10 pts. Five pts 
remain in CR at 208 to 513 days. One pt relapsed with NHL  after 
a CR of 728 days. Four pts developed significant GvHD and died. 
Of the 25 pts, 16 died (6 relapsed disease, 4 GvHD, 3 infection 
and 3 transplant-related toxicity) and 9 are alive (5 in CR and 4 
with relapsed isease). The addition of ATG to low dose TBI and 
FLU was well tolerated and resulted in 100% donor engraftment. 
As in other series of non-myeloablative transplantation, a high 
rate of relapse was obsmwed. Donor engraftment maybe facilitated 
by the addition of ATG to low dose TBI and FLU conditioning. 
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THE ROLE OF DIGITAL PHOTOGRAPHY IN THE DOCUMENTATION OF 
SKIN GRAFT VERSUS HOST DISEASE 
Mavqz~ese~l, 3/1.; Chauvet, D.; DoJ~ob~e, T.; &lpeT~ata, ft.; Childs, R. 
Ste711 Cell Alloge~zeic Tralz.rplalltatio~z Sectiolz, Hematology Bra~zeh, 
NHLBI, NatioJml hzstitutes of Health, DHHS, Bethesda, MD. 
Graft vs host disease (GVHD) remains a serious and potentially 
life threatening complication of allogeneic stem cell transplanta- 
t ion(SCT). Because a significant proportion of complications 
occur in the first 3 months, patients historically have remained 
geographically attached to the transplant center for 100 days or 
more following SCT. Nonmyeloablative or low intensity allo- 
geneic transplants (NST) are generally well tolerated and associat- 
ed with less to.-dcity than coventional myeloablative transplants. As 
a consequence, patients are frequently sent home as early as 2 
months post-transplant with instructions to taper their GVHD 
prophylaxis, to augment a GVT effect. Transplant recipients are 
at risk for delayed onset GVHD during dais period of immuno- 
suppression withdrawal. Members of the transplant center often 
find themselves managing vague symptoms of acute GVHD com- 
municated over the telephone by primary care physicians or the 
patient hemselves. The diagnosis of liver and GI GVHD is readi- 
ly interpertable based on lab findings or clinical parameters such 
as quantity of diarrhea. In contrast, skin rashes may be variable in 
nature and more difficult to interpret in terms of etiology and 
severity. Inaccurate descriptions of skin changes can lead to erro- 
neous diaguosis of acute or chronic skin GVHD which could have 
a deleterious impact on patient outcome. Furthernmre, the incor- 
rect or over treatment of skin GVHD with immunosuppression 
such as corticosteroids and CSA may result in increased suscepti- 
bility to infectious complications and could potentially delay or 
negate a GWI" effect. This frequently occuring diagnostic dilem- 
ma, has led our intsitute to initiate a trial of monitor ing skin 
abnormalities through the use of digital photographs (DP), when 
significant distance limits the ability of patients to quickly reutrn 
to the transplant center. Patients with access to digital cameras 
and the internet, transmit photographs directly to our transplant 
physicians for timely diagnosis and treatment management. This
system provides a mechanism to diagnose and objectively assess 
acute and chronic skin GVHD allowing for both precise manage- 
nrent as well as a method to document response to therapy. Our 
experience suggests that the use of DP may aid in the diagnosis 
and treatment of skin GVHD, particularly in those patients who 
have been discharged home early after NST. 
HISTOCOM PATIBILITY/ALTERNATIVE STEM 
CELL SOURCES 
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DLA-HAPLOIDENTICAL STEM CELL ALLOGRAFTS AFTER ANTI-CD44 
THERAPY AND NONMYELOABLATIVE CONDITIONING IN A PRECLINI- 
CAL CANINE MODEL 
Ft~kz~da, T.; &orb, R.F.; Gooley, T.; ,%~tos, E.B.; S,md~naiev, B.M. 
CliJlieal Research Divisimz, b;red H~ttcbiJTso~z CaJzcev Research C'e~zte'~; 
Seattle, HZA. 
Background: YVe previously reported that engraftment across a 
dog leukocyte antigen (DLA) haplotype-mismatched barrier can 
be achieved after reduced-intensity conditioning with 450 cGy 
,total body irradiation (TBI) plus post-grafting mycophenolate 
mofetil (MMF) / cyclosporine (CSP) (for 35 days) when anti 
CD44 monoelonal antibody (MAh), $5, is added to the regimen 
pretransplant. Here, we studied the effect of anti-CD44 therapy in 
facilitating engraftment of DLA-haploidentical donor cells after 
nonmyeloablative conditioning with 200 cGy TBI  and prolonged 
postgrafting immunosuppression. Methods:  Thirty recipient dogs 
were administered MAb $5, at a dose of 0.2 mg/kgJday from days 
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